Flag of the European Union EU Clinical Trials Register Help

Clinical trials for COPD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    688 result(s) found for: COPD. Displaying page 4 of 35.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-005671-92 Sponsor Protocol Number: PT010005 Start Date*: 2015-11-03
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double Blind, Multi Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52 Week Treatment Period in Subjec...
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) DE (Completed) BE (Completed) PL (Completed) HU (Completed) CZ (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002166-38 Sponsor Protocol Number: 205.301 Start Date*: 2005-01-19
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A 12-week randomized, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled Tiotropium 18µg q.d. in patients with COPD and a concomitant diagnosis of ...
    Medical condition: Patients with COPD (chronic obstructive pulmonary disease) and a concomitant diagnosis of asthma (asthma bronchiale).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002863-32 Sponsor Protocol Number: D6640C00004 Start Date*: 2016-11-04
    Sponsor Name:AstraZeneca AB
    Full Title: A phase IIa, randomised, multi-centre, double blind, placebo-controlled 3 periods, crossover study to investigate the efficacy, pharmacokinetics, safety and tolerability of inhaled AZD8871 adminis...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022110-29 Sponsor Protocol Number: SG006 Start Date*: 2010-10-08
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in...
    Medical condition: Prevention or attenuation of COPD symptoms caused by respiratory viruses
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-004508-37 Sponsor Protocol Number: BY217/M2-128 Start Date*: 2007-01-08
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast in COPD patients treated with tiotropium. A 24-week, double-blind study with 500 µg roflumilast once daily versus placebo.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000611-14 Sponsor Protocol Number: 201314 Start Date*: 2014-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive P...
    Medical condition: in subjects with Chronic Obstructive Pulmonary Disease COPD
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-003938-18 Sponsor Protocol Number: BY217/M2-125 Start Date*: 2006-01-11
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD. A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003606-24 Sponsor Protocol Number: ROF-MD-07 Start Date*: 2012-01-19
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 ?g on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002905-31 Sponsor Protocol Number: RO-2455-405-RD Start Date*: 2011-12-01
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast 500 μg tablets once daily at acute COPD exacerbations treated with standard therapy of oral steroids and antibiotics. A randomised, double-blind, placebo-controlled, parallel-...
    Medical condition: Acute exacerbations of chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    16.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004503-13 Sponsor Protocol Number: KOLprednisolone Start Date*: 2012-12-12
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effect of Glococorticosteroids on physical performance in patients with chronic obstructive pulmonary disease and acute inflammatory response after exercise
    Medical condition: To investigate the effects of prednisone and Solu-Medrol on physical performance in patients with chronic obstructive pulmonary disease(COPD). Furthermore to examine the inflammatory response durin...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004712-10 Sponsor Protocol Number: PT003014 Start Date*: 2015-08-06
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double Blind, Chronic Dosing (24 Weeks), Placebo Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate ...
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    19.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-002275-28 Sponsor Protocol Number: 1237.19 Start Date*: 2014-11-18
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compar...
    Medical condition: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) BE (Completed) NL (Completed) HU (Completed) GB (Completed) ES (Completed) AT (Completed) IE (Completed) LT (Completed) CZ (Completed) LV (Completed) SK (Completed) DE (Completed) SI (Completed) GR (Completed) BG (Completed) HR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020891-43 Sponsor Protocol Number: D3320C00002 Start Date*: 2010-10-07
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients with Moderate to ...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-010864-40 Sponsor Protocol Number: D1882C00003 Start Date*: 2009-06-18
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, double-dummy, placebo-controlled, randomised, multi-centre, 5-way cross-over, single-dose study to investigate the local and systemic effects of inhaled AZD9164 compared to tiotropi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003184-31 Sponsor Protocol Number: Hx-CD20-408 Start Date*: 2007-05-31
    Sponsor Name:Genmab A/S
    Full Title: A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive...
    Medical condition: Moderate to severe stage of Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001122-42 Sponsor Protocol Number: WB29804 Start Date*: 2015-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004610-41 Sponsor Protocol Number: 205.368 Start Date*: 2007-05-28
    Sponsor Name:Boehringer Ingelheim España, S. A.
    Full Title: Ensayo aleatorizado, doble ciego, controlado con placebo de dos años de duración para evaluar cambios en la tolerancia al ejercicio en pacientes con EPOC tratados con Tiotropio (Spiriva® HandiHaler...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003634-15 Sponsor Protocol Number: CQAB149B2211 Start Date*: 2006-09-13
    Sponsor Name:NovartisPharma Services AG
    Full Title: An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration o...
    Medical condition: Mild to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002854-21 Sponsor Protocol Number: CNVA237A2311 Start Date*: 2013-02-19
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/fluticasone p...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002412-10 Sponsor Protocol Number: D5892C00012 Start Date*: 2007-04-25
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, double-dummy, two-way cross-over study evaluating systemic bioavailability and airway clearance of Symbicort® Turbuhaler® 320/9μg/inhalation versus Seretide™ Diskus ™...
    Medical condition: This is a Clinical Pharmacology study to be conducted in one patient group with severe COPD and one group of healthy volunteers.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 02 04:46:40 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA